JP2022526219A - アニリンベースのwdr5タンパク質間相互作用阻害剤、同様物を調製するための方法、およびその使用 - Google Patents
アニリンベースのwdr5タンパク質間相互作用阻害剤、同様物を調製するための方法、およびその使用 Download PDFInfo
- Publication number
- JP2022526219A JP2022526219A JP2021549174A JP2021549174A JP2022526219A JP 2022526219 A JP2022526219 A JP 2022526219A JP 2021549174 A JP2021549174 A JP 2021549174A JP 2021549174 A JP2021549174 A JP 2021549174A JP 2022526219 A JP2022526219 A JP 2022526219A
- Authority
- JP
- Japan
- Prior art keywords
- amino
- substituted
- preparation
- phenyl
- methylpiperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000771599 Homo sapiens WD repeat-containing protein 5 Proteins 0.000 title claims abstract description 39
- 102100029445 WD repeat-containing protein 5 Human genes 0.000 title claims abstract description 39
- 239000003112 inhibitor Substances 0.000 title claims abstract description 18
- 230000004850 protein–protein interaction Effects 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 11
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 title claims 20
- 238000002360 preparation method Methods 0.000 claims abstract description 146
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 206010000830 Acute leukaemia Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 79
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 230000009088 enzymatic function Effects 0.000 claims description 5
- 125000003172 aldehyde group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 12
- 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000001413 cellular effect Effects 0.000 abstract description 7
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000011987 methylation Effects 0.000 abstract description 4
- 238000007069 methylation reaction Methods 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 102000047831 Myeloid Ecotropic Viral Integration Site 1 Human genes 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 261
- 238000005481 NMR spectroscopy Methods 0.000 description 113
- 238000004128 high performance liquid chromatography Methods 0.000 description 76
- 239000007787 solid Substances 0.000 description 75
- 238000012790 confirmation Methods 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 49
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 47
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 25
- 235000010290 biphenyl Nutrition 0.000 description 25
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 16
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 208000032839 leukemia Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- AVPKHOTUOHDTLW-UHFFFAOYSA-N oxane-4-carboxylic acid Chemical compound OC(=O)C1CCOCC1 AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 150000002431 hydrogen Chemical group 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ZPKSAIWDCQVXSQ-UHFFFAOYSA-N (4-aminophenoxy)boronic acid Chemical compound NC1=CC=C(OB(O)O)C=C1 ZPKSAIWDCQVXSQ-UHFFFAOYSA-N 0.000 description 7
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- UQEANKGXXSENNF-UHFFFAOYSA-N 4-bromo-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1F UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- XCHZONVAWUTGGP-UHFFFAOYSA-N methyl 4-[4-(4-methylpiperazin-1-yl)-3-nitrophenyl]benzoate Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)OC)[N+](=O)[O-] XCHZONVAWUTGGP-UHFFFAOYSA-N 0.000 description 6
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000006916 protein interaction Effects 0.000 description 5
- OZKHXLKTMAVPFF-UHFFFAOYSA-N 1-bromo-2,4-difluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC(Br)=C1F OZKHXLKTMAVPFF-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001448 anilines Chemical class 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- DGOYLVBDCVINQZ-UHFFFAOYSA-N oxane-4-carboxamide Chemical compound NC(=O)C1CCOCC1 DGOYLVBDCVINQZ-UHFFFAOYSA-N 0.000 description 4
- KJVBJICWGQIMOZ-UHFFFAOYSA-N 2-fluoro-5-nitroaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1F KJVBJICWGQIMOZ-UHFFFAOYSA-N 0.000 description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- HAOPVEFDLDEFSH-UHFFFAOYSA-N 6-chloro-4-N-(2-fluoro-5-nitrophenyl)pyrimidine-4,5-diamine Chemical compound C1=CC(=C(C=C1[N+](=O)[O-])NC2=C(C(=NC=N2)Cl)N)F HAOPVEFDLDEFSH-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 102000016397 Methyltransferase Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- MKKWZXSLSSSUIY-UHFFFAOYSA-N (4-methoxycarbonylphenoxy)boronic acid Chemical compound COC(=O)C1=CC=C(OB(O)O)C=C1 MKKWZXSLSSSUIY-UHFFFAOYSA-N 0.000 description 2
- SSNCMIDZGFCTST-UHFFFAOYSA-N 1,3-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1F SSNCMIDZGFCTST-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XKPCPQQOUHNXNP-UHFFFAOYSA-N 1-(4-azido-2-nitrophenyl)-4-methylpiperazine Chemical compound CN1CCN(CC1)C1=C(C=C(C=C1)N=[N+]=[N-])[N+](=O)[O-] XKPCPQQOUHNXNP-UHFFFAOYSA-N 0.000 description 2
- PHJCFKABHHJPQV-UHFFFAOYSA-N 1-(4-bromo-2-nitrophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(Br)C=C1[N+]([O-])=O PHJCFKABHHJPQV-UHFFFAOYSA-N 0.000 description 2
- HILKZYIVPOBNJX-UHFFFAOYSA-N 1-[3-[(5-amino-6-chloropyrimidin-4-yl)amino]-4-(4-methylpiperazin-1-yl)phenyl]-N,N-dimethyltriazole-4-carboxamide Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)N3C=C(N=N3)C(=O)N(C)C)NC4=C(C(=NC=N4)Cl)N HILKZYIVPOBNJX-UHFFFAOYSA-N 0.000 description 2
- WGCYRFWNGRMRJA-ZIEKVONGSA-N 1-ethylpiperazine Chemical group CCN1CCN[13CH2][13CH2]1 WGCYRFWNGRMRJA-ZIEKVONGSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- RRDHQVXJWUWDCY-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)-5-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C=C1N RRDHQVXJWUWDCY-UHFFFAOYSA-N 0.000 description 2
- HCTISZQLTGAYOX-UHFFFAOYSA-N 4,6-dichloro-5-nitropyrimidine Chemical group [O-][N+](=O)C1=C(Cl)N=CN=C1Cl HCTISZQLTGAYOX-UHFFFAOYSA-N 0.000 description 2
- XQSJHQXYQAUDFC-UHFFFAOYSA-N 4,6-dichloropyrimidine-5-carbaldehyde Chemical group ClC1=NC=NC(Cl)=C1C=O XQSJHQXYQAUDFC-UHFFFAOYSA-N 0.000 description 2
- MRKLOFJXWXDNEO-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-3-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1[N+]([O-])=O MRKLOFJXWXDNEO-UHFFFAOYSA-N 0.000 description 2
- UYKBXJMJEFXSQW-UHFFFAOYSA-N 4-[2-fluoro-4-(4-methylpiperazin-1-yl)-3-nitrophenyl]aniline Chemical compound CN1CCN(CC1)C2=C(C(=C(C=C2)C3=CC=C(C=C3)N)F)[N+](=O)[O-] UYKBXJMJEFXSQW-UHFFFAOYSA-N 0.000 description 2
- IZZAZCYAOHLKKW-UHFFFAOYSA-N 6-chloro-4-N-(5-nitro-2-piperazin-1-ylphenyl)pyrimidine-4,5-diamine Chemical compound ClC1=C(C(=NC=N1)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCNCC1)N IZZAZCYAOHLKKW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- GKUGDVXVSDBJJC-UHFFFAOYSA-N C(=O)(O)C1=CC(=C(C=C1)OB(O)O)F Chemical group C(=O)(O)C1=CC(=C(C=C1)OB(O)O)F GKUGDVXVSDBJJC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 2
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- ZIAGULZXCIBBFI-UHFFFAOYSA-N N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]quinazolin-4-amine Chemical compound CN1CCN(CC1)C1=C(C=C(C=C1)[N+](=O)[O-])NC1=NC=NC2=CC=CC=C12 ZIAGULZXCIBBFI-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical group OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- OUQJWURFEOSRKU-UHFFFAOYSA-N methyl 1-[4-(4-methylpiperazin-1-yl)-3-nitrophenyl]triazole-4-carboxylate Chemical compound CN1CCN(CC1)C1=C(C=C(C=C1)N1N=NC(=C1)C(=O)OC)[N+](=O)[O-] OUQJWURFEOSRKU-UHFFFAOYSA-N 0.000 description 2
- OJKKQFXKCBBMPW-UHFFFAOYSA-N methyl 4-[5-[(5-amino-6-chloropyrimidin-4-yl)amino]-2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]benzoate Chemical compound CN1CCN(CC1)C2=C(C=C(C(=C2)F)C3=CC=C(C=C3)C(=O)OC)NC4=C(C(=NC=N4)Cl)N OJKKQFXKCBBMPW-UHFFFAOYSA-N 0.000 description 2
- NKYSPBKTVBYALX-UHFFFAOYSA-N methyl 4-[5-[(5-amino-6-chloropyrimidin-4-yl)amino]-2-methyl-4-(4-methylpiperazin-1-yl)phenyl]benzoate Chemical compound CC1=CC(=C(C=C1C2=CC=C(C=C2)C(=O)OC)NC3=C(C(=NC=N3)Cl)N)N4CCN(CC4)C NKYSPBKTVBYALX-UHFFFAOYSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical group CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- OPFDWYCOAMIRPV-UHFFFAOYSA-N (4-pyridin-2-ylphenoxy)boronic acid Chemical group C1=CC(OB(O)O)=CC=C1C1=CC=CC=N1 OPFDWYCOAMIRPV-UHFFFAOYSA-N 0.000 description 1
- YNXJJYOOBWQXKE-UHFFFAOYSA-N (4-pyrimidin-2-ylphenoxy)boronic acid Chemical group OB(O)OC(C=C1)=CC=C1C1=NC=CC=N1 YNXJJYOOBWQXKE-UHFFFAOYSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- LQCPMMRMUCPMAY-UHFFFAOYSA-N 1-[3-[(5-amino-6-chloropyrimidin-4-yl)amino]-4-(4-methylpiperazin-1-yl)phenyl]-N-(3-morpholin-4-ylpropyl)triazole-4-carboxamide Chemical compound CN(CC1)CCN1C(C=CC(N1N=NC(C(NCCCN2CCOCC2)=O)=C1)=C1)=C1NC1=NC=NC(Cl)=C1N LQCPMMRMUCPMAY-UHFFFAOYSA-N 0.000 description 1
- DZHSUMCWDJCSIU-UHFFFAOYSA-N 1-[3-[(5-amino-6-chloropyrimidin-4-yl)amino]-4-(4-methylpiperazin-1-yl)phenyl]-N-[2-(dimethylamino)ethyl]triazole-4-carboxamide Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)N3C=C(N=N3)C(=O)NCCN(C)C)NC4=C(C(=NC=N4)Cl)N DZHSUMCWDJCSIU-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- OOUUWURPSUSDTD-UHFFFAOYSA-N 1-bromo-2,4-difluoro-5-nitrobenzene Chemical group [O-][N+](=O)C1=CC(Br)=C(F)C=C1F OOUUWURPSUSDTD-UHFFFAOYSA-N 0.000 description 1
- AIBRJIYOSLKVFL-UHFFFAOYSA-N 1-bromo-4-fluoro-2-methyl-3-nitrobenzene Chemical compound CC1=C(Br)C=CC(F)=C1[N+]([O-])=O AIBRJIYOSLKVFL-UHFFFAOYSA-N 0.000 description 1
- VMXDJIHJOUZBAW-UHFFFAOYSA-N 1-bromo-4-fluoro-2-methyl-5-nitrobenzene Chemical group CC1=CC(F)=C([N+]([O-])=O)C=C1Br VMXDJIHJOUZBAW-UHFFFAOYSA-N 0.000 description 1
- HNZJIWIXRPBFAN-UHFFFAOYSA-N 1-cyclopropylpiperazine Chemical group C1CC1N1CCNCC1 HNZJIWIXRPBFAN-UHFFFAOYSA-N 0.000 description 1
- KDKGWGUUUVROTO-UHFFFAOYSA-N 1-hydroxypiperazine Chemical group ON1CCNCC1 KDKGWGUUUVROTO-UHFFFAOYSA-N 0.000 description 1
- HCKNAJXCHMACDN-UHFFFAOYSA-N 1-methylpiperidine-4-carboxylic acid Chemical group CN1CCC(C(O)=O)CC1 HCKNAJXCHMACDN-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- VJESLLNEIHGHKX-UHFFFAOYSA-N 2-(2h-pyrimidin-1-yl)ethanamine Chemical group NCCN1CN=CC=C1 VJESLLNEIHGHKX-UHFFFAOYSA-N 0.000 description 1
- INWHDRNGZMHXEZ-UHFFFAOYSA-N 2-(4-methyl-1-piperazinyl)aniline Chemical group C1CN(C)CCN1C1=CC=CC=C1N INWHDRNGZMHXEZ-UHFFFAOYSA-N 0.000 description 1
- CLOMLQDEWGQYID-UHFFFAOYSA-N 2-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]-1H-pyridine-2,3-diamine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)[N+](=O)[O-])C3(C(=CC=CN3)N)N CLOMLQDEWGQYID-UHFFFAOYSA-N 0.000 description 1
- LBLIOXCNMRNFNK-UHFFFAOYSA-N 2-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]-1H-pyrimidine-2,4-diamine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)[N+](=O)[O-])C3(NC=CC(=N3)N)N LBLIOXCNMRNFNK-UHFFFAOYSA-N 0.000 description 1
- IWCIGSVGNMTQDY-UHFFFAOYSA-N 2-[4-[2-[(5-amino-6-chloropyrimidin-4-yl)amino]-4-nitrophenyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCN1CCO)C2=C(C=C(C=C2)[N+](=O)[O-])NC3=C(C(=NC=N3)Cl)N IWCIGSVGNMTQDY-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical group BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- HGNIZPKPCUPQJH-UHFFFAOYSA-N 2-chloro-2h-pyrimidin-1-amine Chemical group NN1C=CC=NC1Cl HGNIZPKPCUPQJH-UHFFFAOYSA-N 0.000 description 1
- LPBDZVNGCNTELM-UHFFFAOYSA-N 2-chloropyrimidin-4-amine Chemical group NC1=CC=NC(Cl)=N1 LPBDZVNGCNTELM-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical group OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- CDDCEBKBCZFLMP-UHFFFAOYSA-N 3-nitro-4-phenylbenzoic acid Chemical group [O-][N+](=O)C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 CDDCEBKBCZFLMP-UHFFFAOYSA-N 0.000 description 1
- PPAULTVPKLVLII-UHFFFAOYSA-N 4,5-diaminopyrimidine Chemical compound NC1=CN=CN=C1N PPAULTVPKLVLII-UHFFFAOYSA-N 0.000 description 1
- FIMUTBLUWQGTIJ-UHFFFAOYSA-N 4,6-dichloro-2-methylpyrimidine Chemical group CC1=NC(Cl)=CC(Cl)=N1 FIMUTBLUWQGTIJ-UHFFFAOYSA-N 0.000 description 1
- NIGDWBHWHVHOAD-UHFFFAOYSA-N 4,6-dichloropyrimidin-5-amine Chemical compound NC1=C(Cl)N=CN=C1Cl NIGDWBHWHVHOAD-UHFFFAOYSA-N 0.000 description 1
- IPEBKIMUIHKZJP-UHFFFAOYSA-N 4,6-dichloropyrimidine-5-carbonitrile Chemical group ClC1=NC=NC(Cl)=C1C#N IPEBKIMUIHKZJP-UHFFFAOYSA-N 0.000 description 1
- YPHJCNMTQDKQBN-UHFFFAOYSA-N 4-(2,4-difluoro-3-nitrophenyl)aniline Chemical compound C1=CC(=CC=C1C2=C(C(=C(C=C2)F)[N+](=O)[O-])F)N YPHJCNMTQDKQBN-UHFFFAOYSA-N 0.000 description 1
- KCQAFXXADXYFBW-UHFFFAOYSA-N 4-(2,4-difluoro-3-nitrophenyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(F)C([N+]([O-])=O)=C1F KCQAFXXADXYFBW-UHFFFAOYSA-N 0.000 description 1
- UPMHYAMHJGLFQB-UHFFFAOYSA-N 4-(4-fluoro-2-methyl-3-nitrophenyl)-N,N-dimethylbenzamide Chemical compound CC1=C(C=CC(=C1[N+](=O)[O-])F)C2=CC=C(C=C2)C(=O)N(C)C UPMHYAMHJGLFQB-UHFFFAOYSA-N 0.000 description 1
- HZCIZLYPWWSDRC-UHFFFAOYSA-N 4-N-[5-bromo-2-(4-methylpiperazin-1-yl)phenyl]-6-chloropyrimidine-4,5-diamine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)Br)NC3=C(C(=NC=N3)Cl)N HZCIZLYPWWSDRC-UHFFFAOYSA-N 0.000 description 1
- IFCFOGLLPSIERY-UHFFFAOYSA-N 4-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]-1H-pyrimidine-4,5-diamine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)[N+](=O)[O-])C3(C(=CNC=N3)N)N IFCFOGLLPSIERY-UHFFFAOYSA-N 0.000 description 1
- SGDIMMYXCWHRHO-UHFFFAOYSA-N 4-[3-[(5-amino-6-chloropyrimidin-4-yl)amino]-4-(4-methylpiperazin-1-yl)phenyl]benzoic acid Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)O)NC4=C(C(=NC=N4)Cl)N SGDIMMYXCWHRHO-UHFFFAOYSA-N 0.000 description 1
- WLNUGCPWGREJDW-UHFFFAOYSA-N 4-[3-amino-2-methyl-4-(4-methylpiperazin-1-yl)phenyl]-N,N-dimethylbenzamide Chemical compound CC1=C(C=CC(=C1N)N2CCN(CC2)C)C3=CC=C(C=C3)C(=O)N(C)C WLNUGCPWGREJDW-UHFFFAOYSA-N 0.000 description 1
- ALYXBNQXDVPOQX-UHFFFAOYSA-N 4-[5-bromo-2-(4-methylpiperazin-1-yl)phenyl]-6-chloro-1H-pyrimidine-4,5-diamine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)Br)C3(C(=C(NC=N3)Cl)N)N ALYXBNQXDVPOQX-UHFFFAOYSA-N 0.000 description 1
- VFFMTCYJVZHTOI-UHFFFAOYSA-N 4-chloro-6-[2-(4-methylpiperazin-1-yl)-5-nitroanilino]pyrimidine-5-carbaldehyde Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)[N+](=O)[O-])NC3=C(C(=NC=N3)Cl)C=O VFFMTCYJVZHTOI-UHFFFAOYSA-N 0.000 description 1
- IRIRMWPLTZADAJ-UHFFFAOYSA-N 4-chloro-6-[2-(4-methylpiperazin-1-yl)-5-nitroanilino]pyrimidine-5-carbonitrile Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)[N+](=O)[O-])NC3=C(C(=NC=N3)Cl)C#N IRIRMWPLTZADAJ-UHFFFAOYSA-N 0.000 description 1
- LHGMCUVJFRBVBH-UHFFFAOYSA-N 4-chloropyrimidin-5-amine Chemical group NC1=CN=CN=C1Cl LHGMCUVJFRBVBH-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- LLIOADBCFIXIEU-UHFFFAOYSA-N 4-fluoro-3-nitroaniline Chemical compound NC1=CC=C(F)C([N+]([O-])=O)=C1 LLIOADBCFIXIEU-UHFFFAOYSA-N 0.000 description 1
- KNWWGBNAUNTSRV-UHFFFAOYSA-N 4-methylpiperazine-1-carboxylic acid Chemical group CN1CCN(C(O)=O)CC1 KNWWGBNAUNTSRV-UHFFFAOYSA-N 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical group C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
- QRSKVMNMLVQJPL-UHFFFAOYSA-N 5-bromo-2-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(Br)C=C1N QRSKVMNMLVQJPL-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- IQELAECAESBPFF-UHFFFAOYSA-N 6-chloro-2-methyl-4-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidine-4,5-diamine Chemical compound ClC1=C(C(=NC(=N1)C)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C)N IQELAECAESBPFF-UHFFFAOYSA-N 0.000 description 1
- KZQZVZSJRDXWNR-UHFFFAOYSA-N 6-chloro-2-methyl-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-4-amine Chemical compound ClC1=CC(=NC(=N1)C)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C KZQZVZSJRDXWNR-UHFFFAOYSA-N 0.000 description 1
- JUHIUTSEIVYBOY-UHFFFAOYSA-N 6-chloro-4-N-(2-morpholin-4-yl-5-nitrophenyl)pyrimidine-4,5-diamine Chemical compound ClC1=C(C(=NC=N1)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCOCC1)N JUHIUTSEIVYBOY-UHFFFAOYSA-N 0.000 description 1
- YHEAXHJCJNRNGX-UHFFFAOYSA-N 6-chloro-4-N-[2-(4-cyclopropylpiperazin-1-yl)-5-nitrophenyl]pyrimidine-4,5-diamine Chemical compound C1CC1N2CCN(CC2)C3=C(C=C(C=C3)[N+](=O)[O-])NC4=C(C(=NC=N4)Cl)N YHEAXHJCJNRNGX-UHFFFAOYSA-N 0.000 description 1
- QECQLKCHZLSHMB-UHFFFAOYSA-N 6-chloro-4-N-[2-(4-ethylpiperazin-1-yl)-5-nitrophenyl]pyrimidine-4,5-diamine Chemical compound ClC1=C(C(=NC=N1)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)CC)N QECQLKCHZLSHMB-UHFFFAOYSA-N 0.000 description 1
- FETAAEVCIMLACI-UHFFFAOYSA-N 6-chloro-4-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidine-2,4-diamine Chemical compound ClC1=CC(=NC(=N1)N)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C FETAAEVCIMLACI-UHFFFAOYSA-N 0.000 description 1
- OPQOTHVRDSSYJQ-UHFFFAOYSA-N 6-chloro-4-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidine-4,5-diamine Chemical compound ClC1=C(C(=NC=N1)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C)N OPQOTHVRDSSYJQ-UHFFFAOYSA-N 0.000 description 1
- ATLRODXDTLDDGP-UHFFFAOYSA-N 6-chloro-4-N-[2-(4-methylpiperazin-1-yl)-5-pyridin-4-ylphenyl]pyrimidine-4,5-diamine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=NC=C3)NC4=C(C(=NC=N4)Cl)N ATLRODXDTLDDGP-UHFFFAOYSA-N 0.000 description 1
- PMDHDNMBHIOYJU-UHFFFAOYSA-N 6-chloro-4-N-[2-(4-methylpiperazin-1-yl)-5-pyrimidin-5-ylphenyl]pyrimidine-4,5-diamine Chemical compound ClC1=C(C(=NC=N1)NC1=C(C=CC(=C1)C=1C=NC=NC=1)N1CCN(CC1)C)N PMDHDNMBHIOYJU-UHFFFAOYSA-N 0.000 description 1
- VSATVFWBORQUKI-UHFFFAOYSA-N 6-chloro-4-N-[5-(4-methoxyphenyl)-2-(4-methylpiperazin-1-yl)phenyl]pyrimidine-4,5-diamine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=C(C=C3)OC)NC4=C(C(=NC=N4)Cl)N VSATVFWBORQUKI-UHFFFAOYSA-N 0.000 description 1
- BAAZVLAONCRZLV-UHFFFAOYSA-N 6-chloro-4-N-[5-nitro-2-(4-phenylpiperazin-1-yl)phenyl]pyrimidine-4,5-diamine Chemical compound C1CN(CCN1C2=CC=CC=C2)C3=C(C=C(C=C3)[N+](=O)[O-])NC4=C(C(=NC=N4)Cl)N BAAZVLAONCRZLV-UHFFFAOYSA-N 0.000 description 1
- QPINVLYDWYOXQE-UHFFFAOYSA-N 6-chloro-5-methoxy-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-4-amine Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)[N+](=O)[O-])NC3=C(C(=NC=N3)Cl)OC QPINVLYDWYOXQE-UHFFFAOYSA-N 0.000 description 1
- SHUJKZMPADHWOG-UHFFFAOYSA-N 6-chloro-5-methyl-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-4-amine Chemical compound ClC1=C(C(=NC=N1)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C)C SHUJKZMPADHWOG-UHFFFAOYSA-N 0.000 description 1
- DAUZFEGSOBBSLY-UHFFFAOYSA-N 6-chloro-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]-5-nitropyrimidin-4-amine Chemical compound ClC1=C(C(=NC=N1)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C)[N+](=O)[O-] DAUZFEGSOBBSLY-UHFFFAOYSA-N 0.000 description 1
- CRJMNAKUDQZNQC-UHFFFAOYSA-N 6-chloro-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-4-amine Chemical compound ClC1=CC(=NC=N1)NC1=C(C=CC(=C1)[N+](=O)[O-])N1CCN(CC1)C CRJMNAKUDQZNQC-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- IPSVUZYXERJIGV-UHFFFAOYSA-N CC1(NC)NC=NC(NC(C=C(C=C2)[N+]([O-])=O)=C2N2CCN(C)CC2)=C1 Chemical compound CC1(NC)NC=NC(NC(C=C(C=C2)[N+]([O-])=O)=C2N2CCN(C)CC2)=C1 IPSVUZYXERJIGV-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 101100033032 Caenorhabditis elegans rbbp-5 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000902641 Homo sapiens Protein dpy-30 homolog Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- HIGOPQXVAIVBFS-UHFFFAOYSA-N N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-2-amine Chemical compound CN1CCN(CC1)C1=C(C=C(C=C1)[N+](=O)[O-])NC1=NC=CC=N1 HIGOPQXVAIVBFS-UHFFFAOYSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- HLTWSCKFOBUFOO-UHFFFAOYSA-N OB(O)OC(C=CC=C1)=C1C1=COC=C1 Chemical group OB(O)OC(C=CC=C1)=C1C1=COC=C1 HLTWSCKFOBUFOO-UHFFFAOYSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical group NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 102100022946 Protein dpy-30 homolog Human genes 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical group C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- VVSHXMHKOZDWCQ-UHFFFAOYSA-N methyl 1-[3-[(5-amino-6-chloropyrimidin-4-yl)amino]-4-(4-methylpiperazin-1-yl)phenyl]triazole-4-carboxylate Chemical compound NC=1C(=NC=NC=1Cl)NC=1C=C(C=CC=1N1CCN(CC1)C)N1N=NC(=C1)C(=O)OC VVSHXMHKOZDWCQ-UHFFFAOYSA-N 0.000 description 1
- MJYBYXZQUPJBHB-UHFFFAOYSA-N methyl 1-[3-amino-4-(4-methylpiperazin-1-yl)phenyl]triazole-4-carboxylate Chemical compound CN1CCN(CC1)C2=C(C=C(C=C2)N3C=C(N=N3)C(=O)OC)N MJYBYXZQUPJBHB-UHFFFAOYSA-N 0.000 description 1
- WUDYSWUIDQBKLI-UHFFFAOYSA-N methyl 4-(2,4-difluoro-5-nitrophenyl)benzoate Chemical compound COC(=O)C1=CC=C(C=C1)C2=CC(=C(C=C2F)F)[N+](=O)[O-] WUDYSWUIDQBKLI-UHFFFAOYSA-N 0.000 description 1
- SWXASXZCINPZMQ-UHFFFAOYSA-N methyl 4-[2-fluoro-4-(4-methylpiperazin-1-yl)-5-nitrophenyl]benzoate Chemical compound CN1CCN(CC1)C2=C(C=C(C(=C2)F)C3=CC=C(C=C3)C(=O)OC)[N+](=O)[O-] SWXASXZCINPZMQ-UHFFFAOYSA-N 0.000 description 1
- VRSRTPBVFCEAOC-UHFFFAOYSA-N methyl 4-[2-methyl-4-(4-methylpiperazin-1-yl)-5-nitrophenyl]benzoate Chemical compound CC1=CC(=C(C=C1C2=CC=C(C=C2)C(=O)OC)[N+](=O)[O-])N3CCN(CC3)C VRSRTPBVFCEAOC-UHFFFAOYSA-N 0.000 description 1
- ZSIHKYSRLITJDL-UHFFFAOYSA-N methyl 4-[3-amino-2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]benzoate Chemical compound CN1CCN(CC1)C2=C(C(=C(C=C2)C3=CC=C(C=C3)C(=O)OC)F)N ZSIHKYSRLITJDL-UHFFFAOYSA-N 0.000 description 1
- WDMMVHKCDIGPSY-UHFFFAOYSA-N methyl 4-[3-amino-4-(4-methylpiperazin-1-yl)phenyl]benzoate Chemical compound NC=1C=C(C=CC=1N1CCN(CC1)C)C1=CC=C(C=C1)C(=O)OC WDMMVHKCDIGPSY-UHFFFAOYSA-N 0.000 description 1
- HVQKEQNWBSDFNF-UHFFFAOYSA-N methyl 4-[5-amino-2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]benzoate Chemical compound CN1CCN(CC1)C2=C(C=C(C(=C2)F)C3=CC=C(C=C3)C(=O)OC)N HVQKEQNWBSDFNF-UHFFFAOYSA-N 0.000 description 1
- VEPWXBCDVIHNLH-UHFFFAOYSA-N methyl 4-[5-amino-2-methyl-4-(4-methylpiperazin-1-yl)phenyl]benzoate Chemical compound CC1=CC(=C(C=C1C2=CC=C(C=C2)C(=O)OC)N)N3CCN(CC3)C VEPWXBCDVIHNLH-UHFFFAOYSA-N 0.000 description 1
- IMAKHNTVDGLIRY-UHFFFAOYSA-N methyl prop-2-ynoate Chemical compound COC(=O)C#C IMAKHNTVDGLIRY-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 1
- 238000013392 nude mouse xenograft model Methods 0.000 description 1
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical group NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical group C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
YはCまたはNを表し、
R1、R2、およびR3は、同一または互いに異なっており、そして、それぞれ単独で、水素、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシで置換されたC1-C6アルキル、ニトロ、ハロ、シアノ、アルデヒド基、ヒドロキシル、-NR7R8、またはR2およびR3を結合させることによって形成される
R4は、モルホリニル、ピペラジニル、4-置換ピペラジニル、4-置換ホモピペラジニル、3-置換ピペラジニル、または2-置換ピペラジニルを表し、ここで、置換基は、C1-C4アルキル、3員から7員のシクロアルキル、ヒドロキシアルキル、またはフェニルであり;
R5は、ニトロ、アミノ、フェニル、置換フェニル、5員から6員の酸素芳香族複素環または窒素芳香族複素環、置換された5員から6員の酸素芳香族複素環または窒素芳香族複素環、あるいは-NHCOR9を表し;ここで、R9は、ヒドロキシル、C1-C6アルコキシ、フェニル、置換フェニル、5員から6員の酸素芳香族複素環または窒素芳香族複素環、あるいは置換された5員から6員の酸素芳香族複素環または窒素芳香族複素環を表し、ここで、置換基は、C1-C4アルキル、C1-C4アルコキシ、ハロ、シアノ、―NHCOR10、―CONR11R12、または―COOR10であり、ここで、R10は、水素、C1-C6アルキル、C1-C6アミノ置換アルキル、3員から7員のシクロアルキル、3員から7員の窒素複素環または酸素複素環、あるいはフェニルを表し;そして、R11とR12は、水素、C1-C6アルキル、フェニルまたは置換フェニル、あるいは、置換されているかまたは置換されていない3員から7員の窒素複素環または酸素複素環、あるいは、R11とR12によって形成される3員から7員の窒素複素環または酸素複素環を単独で表し;そして、
R6は、水素、ハロ、メチル、トリフルオロメチル、アミノ、または置換アミノを表し、ここで、置換基は、C1-C4アルキル、またはアリルであり;
R1、R2、およびR3は、同一または互いに異なっており、そして、それぞれ単独で、水素、ハロ、メチル、ニトロ、シアノ、アルデヒド基、メトキシル、-NR7R8、またはR2とR3を結合させることによって形成される
R4は、好ましくは、モルホリニル、ピペラジニル、または4-置換ピペラジニルであり、ここで、置換基は、メチル、エチル、シクロプロピル、ヒドロキシエチル、またはフェニルであり;
R5は、好ましくは、ニトロ、アミノ、―NHCOR9、フリル、ピリミジニル、ピリジニル、置換トリアゾリル、または置換フェニルであり、ここで、置換基は、一置換ハロまたは二置換ハロ、―NHCOR10、―CONR11R12、または―COOR10であり、ここで、R9は、フェニルを表し;R10は、水素、C1-C6アルキル、C1-C6アミノ置換アルキル、3員から7員のシクロアルキル、3員から7員の窒素複素環または酸素複素環、あるいはフェニルを表し;そして、R11とR12は、水素、C1-C6アルキル、フェニルまたは置換フェニル、あるいは、置換されているかまたは置換されていない3員から7員の窒素複素環または酸素複素環、あるいは、R11およびR12を結合させることによって形成される3員から7員の窒素複素環または酸素複素環を表わす。
N4-ジメチル-N6-(2-(4-メチルピペラジン-1-イル)-5-ニトロフェニル)ピリミジン-4,6-ジアミン
Claims (10)
- アニリンベースのWDR5タンパク質間相互作用阻害剤であって、前記アニリンベースのWDR5タンパク質間相互作用阻害剤は、一般式(I)によって表わされる化合物、その薬学的に許容可能な塩、そのプロドラッグ、かつ水和物または溶媒和化合物を含み、:
YはCまたはNを表し、
R1、R2、およびR3は、水素、C1-C6アルキル、C3-C6シクロアルキル、C1-C6アルコキシルで置換されたC1-C6アルキル、ニトロ、ハロ、シアノ、アルデヒド基、ヒドロキシル、-NR7R8、またはR2およびR3を結合させることによって形成される
R4は、モルホリニル、ピペラジニル、4-置換ピペラジニル、4-置換ホモピペラジニル、3-置換ピペラジニル、または2-置換ピペラジニルを表し、ここで、置換基は、C1-C4アルキル、3員から7員のシクロアルキル、ヒドロキシアルキル、またはフェニルであり;
R5は、ニトロ、アミノ、フェニル、置換フェニル、5員から6員の酸素芳香族複素環または窒素芳香族複素環、置換された5員から6員の酸素芳香族複素環または窒素芳香族複素環、あるいは-NHCOR9を表し;ここで、R9は、ヒドロキシル、C1-C6アルコキシ、フェニル、置換フェニル、5員から6員の酸素芳香族複素環または窒素芳香族複素環、あるいは置換された5員から6員の酸素芳香族複素環または窒素芳香族複素環を表し、ここで、置換基は、C1-C4アルキル、C1-C4アルコキシ、ハロ、シアノ、―NHCOR10、―CONR11R12、または―COOR10であり、ここで、R10は、水素、C1-C6アルキル、C1-C6アミノ置換アルキル、3員から7員のシクロアルキル、3員から7員の窒素複素環または酸素複素環、あるいはフェニルを表し;そして、R11とR12は、水素、C1-C6アルキル、フェニルまたは置換フェニル、あるいは、置換されているかまたは置換されていない3員から7員の窒素複素環または酸素複素環、あるいは、R11およびR12を結合させることによって形成される3員から7員の窒素複素環または酸素複素環を表し;そして、
R6は、水素、ハロ、メチル、トリフルオロメチル、アミノ、または置換アミノを表し、ここで、置換基は、C1-C4アルキル、またはアリルである、
アニリンベースのWDR5タンパク質間相互作用阻害剤。 - R4が、モルホリニル、ピペラジニル、または4-置換ピペラジニルを表し、ここで、置換基が、メチル、エチル、シクロプロピル、ヒドロキシエチル、またはフェニルである、請求項1に記載のアニリンベースのWDR5タンパク質間相互作用阻害剤。
- R5が、ニトロ、アミノ、―NHCOR9、フリル、ピリミジニル、ピリジニル、置換トリアゾリル、または置換フェニルを表し、ここで、置換基が、一置換ハロまたは二置換ハロ、―NHCOR10、―CONR11R12、または―COOR10であり、ここで、R9が、フェニルを表し、R10が、水素、C1-C6アルキル、C1-C6アミノ置換アルキル、3員から7員のシクロアルキル、3員から7員の窒素複素環または酸素複素環、あるいはフェニルを表し;そして、R11とR12が、水素、C1-C6アルキル、フェニルまたは置換フェニル、あるいは、置換されているかまたは置換されていない3員から7員の窒素複素環または酸素複素環、あるいは、R11およびR12を結合させることによって形成される3員から7員の窒素複素環または酸素複素環を表わす、請求項1に記載のアニリンベースのWDR5タンパク質間相互作用阻害剤。
- 前記薬学的に許容可能な塩が、一般式(I)によって表わされる無機酸塩または有機酸塩であり;ここで、前記無機酸塩が、塩酸塩、臭化水素酸塩、または硫酸塩であり;そして、前記有機酸塩が、酢酸塩、乳酸塩、コハク酸塩、フマル酸塩、マレイン酸塩、クエン酸塩、安息香酸塩、メタンスルホン酸塩、またはp-トルエンスルホン酸塩である、請求項1に記載のアニリンベースのWDR5タンパク質間相互作用阻害剤。
- 請求項1に記載のアニリンベースのWDR5タンパク質間相互作用阻害剤を含む、医薬組成物。
- WDR5酵素機能に関連する適応症を処置するための薬物の調製における、請求項1に記載のアニリンベースのWDR5タンパク質間相互作用阻害剤の使用。
- 関連する前記適応症が、血液腫瘍である、請求項8に記載のWDR5酵素機能に関連する適応症。
- 前記血液腫瘍が、急性白血病である、請求項9に記載のWDR5酵素機能に関連する適応症。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910139980.6 | 2019-02-26 | ||
CN201910139980.6A CN109734674B (zh) | 2019-02-26 | 2019-02-26 | 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 |
PCT/CN2019/079160 WO2020172932A1 (zh) | 2019-02-26 | 2019-03-22 | 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022526219A true JP2022526219A (ja) | 2022-05-24 |
Family
ID=66368322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021549174A Pending JP2022526219A (ja) | 2019-02-26 | 2019-03-22 | アニリンベースのwdr5タンパク質間相互作用阻害剤、同様物を調製するための方法、およびその使用 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220152027A1 (ja) |
EP (1) | EP3932910A4 (ja) |
JP (1) | JP2022526219A (ja) |
KR (1) | KR20210137064A (ja) |
CN (1) | CN109734674B (ja) |
AU (1) | AU2019431157A1 (ja) |
BR (1) | BR112021016861A2 (ja) |
CA (1) | CA3131285A1 (ja) |
CL (1) | CL2021002234A1 (ja) |
CO (1) | CO2021012375A2 (ja) |
IL (1) | IL285852A (ja) |
MX (1) | MX2021010218A (ja) |
SG (1) | SG11202109305XA (ja) |
WO (1) | WO2020172932A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023097422A1 (zh) * | 2021-11-30 | 2023-06-08 | 首都医科大学附属北京口腔医院 | Kdm6b的多肽序列及对间充质干细胞功能的调控应用 |
US20230293539A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof |
WO2024015478A2 (en) * | 2022-07-14 | 2024-01-18 | Huyabio International, Llc | Combination therapies of wdr5 inhibitors and pd-1 inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108715585A (zh) * | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011149827A1 (en) * | 2010-05-24 | 2011-12-01 | Glaxosmithkline Llc | Compounds and methods |
CN104844573A (zh) * | 2015-04-17 | 2015-08-19 | 中国药科大学 | 嘧啶类btk抑制剂、其制备方法及医药用途 |
US10980807B2 (en) * | 2016-02-09 | 2021-04-20 | Inventisbio Llc | Inhibitor of indoleamine-2,3-dioxygenase (IDO) |
CN107382840B (zh) * | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
-
2019
- 2019-02-26 CN CN201910139980.6A patent/CN109734674B/zh active Active
- 2019-03-22 US US17/434,353 patent/US20220152027A1/en active Pending
- 2019-03-22 BR BR112021016861A patent/BR112021016861A2/pt unknown
- 2019-03-22 KR KR1020217030807A patent/KR20210137064A/ko not_active Application Discontinuation
- 2019-03-22 EP EP19917469.9A patent/EP3932910A4/en active Pending
- 2019-03-22 MX MX2021010218A patent/MX2021010218A/es unknown
- 2019-03-22 CA CA3131285A patent/CA3131285A1/en active Pending
- 2019-03-22 AU AU2019431157A patent/AU2019431157A1/en active Pending
- 2019-03-22 SG SG11202109305XA patent/SG11202109305XA/en unknown
- 2019-03-22 JP JP2021549174A patent/JP2022526219A/ja active Pending
- 2019-03-22 WO PCT/CN2019/079160 patent/WO2020172932A1/zh unknown
-
2021
- 2021-08-24 CL CL2021002234A patent/CL2021002234A1/es unknown
- 2021-08-25 IL IL285852A patent/IL285852A/en unknown
- 2021-09-22 CO CONC2021/0012375A patent/CO2021012375A2/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108715585A (zh) * | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
IL285852A (en) | 2021-10-31 |
KR20210137064A (ko) | 2021-11-17 |
CN109734674A (zh) | 2019-05-10 |
BR112021016861A2 (pt) | 2021-11-30 |
WO2020172932A1 (zh) | 2020-09-03 |
AU2019431157A1 (en) | 2021-10-14 |
CN109734674B (zh) | 2022-08-26 |
CL2021002234A1 (es) | 2022-05-27 |
EP3932910A1 (en) | 2022-01-05 |
CA3131285A1 (en) | 2020-09-03 |
MX2021010218A (es) | 2021-10-26 |
SG11202109305XA (en) | 2021-09-29 |
US20220152027A1 (en) | 2022-05-19 |
CO2021012375A2 (es) | 2021-11-19 |
EP3932910A4 (en) | 2022-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016315881B2 (en) | Small molecule inhibitors of DYRK1A and uses thereof | |
JP5560278B2 (ja) | キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル | |
KR101257158B1 (ko) | 단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체 | |
JP2019108346A (ja) | リジン特異的なデメチラーゼ−1の阻害剤 | |
BR112016025248B1 (pt) | Compostos inibidores de demetilase lisina-específica-1, composição farmacêutica e seus usos | |
JP2022526219A (ja) | アニリンベースのwdr5タンパク質間相互作用阻害剤、同様物を調製するための方法、およびその使用 | |
EP2958898A1 (en) | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | |
JP2010522186A (ja) | 化合物 | |
JP3990061B2 (ja) | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンa2受容体拮抗剤 | |
US20190152973A1 (en) | Novel heterocyclic derivative compound and use thereof | |
JP2023512038A (ja) | 化合物及びその使用 | |
CN107739368B (zh) | N-取代-5-((4-取代嘧啶-2-基)氨基)吲哚类衍生物及其制备方法和用途 | |
JP2023545784A (ja) | Jakキナーゼ阻害剤としての小分子化合物及びその用途 | |
US8889870B2 (en) | Kinase inhibitors | |
WO2020208138A1 (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
CN111662275B (zh) | 苯磺酰胺类idh突变体抑制剂、其制备方法和用途 | |
CN113461687B (zh) | 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途 | |
WO2023085392A1 (ja) | 抗SARS-CoV-2薬 | |
CN111560013B (zh) | 一种自噬抑制剂及其应用 | |
TWI432192B (zh) | 新穎〔1,2-d〕咪唑蒽醌衍生物、製備方法及其應用 | |
WO2024114574A1 (zh) | 一种高选择性的plk4抑制剂及制备方法和应用 | |
CN116813621A (zh) | 9h嘌呤类化合物及其药物组合物和用途 | |
CN117730083A (zh) | 用作map4k1抑制剂的嘧啶化合物 | |
EP4097102A1 (en) | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists | |
CN117343058A (zh) | 取代7-氮杂吲哚-3-羧酸类Mcl-1蛋白抑制剂及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211001 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220518 |
|
RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20221221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240321 |